Keyword
MRONJ

Medication-related Osteonecrosis in the Oncology Patient: Inter-professional Communication in Addressing Lesion Stability May Be More Important in Management Than Lesion Resolution

Abstract Patients who are diagnosed with MRONJ while being treated with bone modifying agents(BMAs) at oncologic doses, there is insufficient evidence to support or refute the discontinuation of BMAs. Administration of the BMA may be deferred at the discretion of…